Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shilpa Medicare Limited ( (IN:SHILPAMED) ) has provided an announcement.
Shilpa Medicare Limited has received initial authorization from Europe for its Rotigotine transdermal patch, a generic version of Neupro®, used to treat Restless Legs Syndrome and Parkinson’s disease. This milestone marks Shilpa’s first transdermal patch to gain marketing authorization in Europe, with a targeted launch in FY27, and represents a significant step in expanding its market presence in the European pharmaceutical sector.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is a prominent Indian pharmaceutical company specializing in the development, manufacture, and marketing of APIs, formulations, and biologics, particularly in the oncology, infectious diseases, and specialty segments. The company is known for its expertise in complex generics, novel drug delivery systems, and CDMO services, serving patients in over 80 countries.
Average Trading Volume: 29,513
Technical Sentiment Signal: Hold
Current Market Cap: 65.49B INR
For detailed information about SHILPAMED stock, go to TipRanks’ Stock Analysis page.